Benitec Biopharma (BNTC) EBT Margin (2019 - 2023)

Benitec Biopharma (BNTC) posted EBT Margin of 234828.57% for Q2 2023, down 2070.62% sequentially from 10818.52% in Q1 2023.

Benitec Biopharma (BNTC) EBT Margin (2019 - 2023) Analysis & Trends

Benitec Biopharma has reported EBT Margin for 5 years, with the latest figure at 234828.57% in Q2 2023.

Quarterly EBT Margin changed N/A year-over-year to 234828.57% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 5689871.43% (down 565679349.0% YoY) and the FY2023 annual result came in at 41292.0%, up 777512.0% from the prior year.
EBT Margin declined to 234828.57% in Q2 2023 per BNTC's latest filing, from 10818.52% in the prior quarter.
Over five years, EBT Margin peaked at 46220.0% in Q2 2020 and troughed at 380100.0% in Q1 2021.
A 5-year average of 94732.58% and a median of 10818.52% in 2023 frame the typical range for EBT Margin.
The sharpest annual moves came in 2021 and 2022: EBT Margin plunged 37256071 bps in 2021, then surged 37260000 bps in 2022.
Over 5 years, EBT Margin stood at 2741.56% in 2019, then tumbled by 12966 bps to 358200.0% in 2020, then soared by 94 bps to 19948.0% in 2021, then tumbled by 127 bps to 45264.29% in 2022, then plunged by 419 bps to 234828.57% in 2023.
According to Business Quant data, EBT Margin over the past three periods registered 234828.57%, 10818.52%, and 45264.29% for Q2 2023, Q1 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Benitec Biopharma	577.39 Mn	388.49 Mn	-	-

Download Data